Aligos Therapeutics, Inc.
ALGS
$10.10
$0.25992.64%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -74.18M | -53.26M | -131.21M | -76.95M | -75.74M |
| Total Depreciation and Amortization | 1.79M | 1.79M | 1.88M | 1.98M | 1.99M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 3.95M | -24.14M | 53.55M | -5.17M | -3.61M |
| Change in Net Operating Assets | -6.48M | -3.30M | -4.96M | -4.86M | -7.88M |
| Cash from Operations | -74.92M | -78.91M | -80.74M | -85.00M | -85.23M |
| Capital Expenditure | -206.00K | -104.00K | -130.00K | -109.00K | -95.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -7.00K |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -52.91M | 26.40M | -18.15M | -38.15M | -48.56M |
| Cash from Investing | -53.12M | 26.30M | -18.28M | -38.26M | -48.67M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -49.00K | -64.00K | -83.00K | -44.00K | -60.00K |
| Issuance of Common Stock | 101.88M | 102.18M | 438.00K | 17.83M | 17.83M |
| Repurchase of Common Stock | -176.00K | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | 70.41M | 70.41M |
| Cash from Financing | 101.66M | 102.12M | 355.00K | 88.19M | 88.18M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -26.38M | 49.51M | -98.67M | -35.06M | -45.72M |